Alps Advisors Inc. Buys 2,583 Shares of GW Pharmaceuticals PLC- (GWPH)
Alps Advisors Inc. increased its stake in GW Pharmaceuticals PLC- (NASDAQ:GWPH) by 7.6% in the 2nd quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 36,523 shares of the biopharmaceutical company’s stock after purchasing an additional 2,583 shares during the quarter. Alps Advisors Inc. owned about 0.13% of GW Pharmaceuticals PLC- worth $5,096,000 at the end of the most recent quarter.
Other hedge funds and other institutional investors also recently made changes to their positions in the company. WealthTrust Fairport LLC bought a new stake in GW Pharmaceuticals PLC- during the first quarter valued at $104,000. Stratos Wealth Partners LTD. boosted its stake in GW Pharmaceuticals PLC- by 216.0% during the first quarter. Stratos Wealth Partners LTD. now owns 948 shares of the biopharmaceutical company’s stock valued at $107,000 after buying an additional 648 shares during the period. BNP Paribas Arbitrage SA boosted its stake in GW Pharmaceuticals PLC- by 497.0% during the second quarter. BNP Paribas Arbitrage SA now owns 1,200 shares of the biopharmaceutical company’s stock valued at $167,000 after buying an additional 999 shares during the period. Comerica Bank bought a new stake in GW Pharmaceuticals PLC- during the second quarter valued at $203,000. Finally, Suntrust Banks Inc. bought a new stake in GW Pharmaceuticals PLC- during the first quarter valued at $227,000. Institutional investors own 75.41% of the company’s stock.
Shares of GWPH stock opened at $146.62 on Friday. The company has a debt-to-equity ratio of 0.01, a current ratio of 8.67 and a quick ratio of 8.21. GW Pharmaceuticals PLC- has a 12-month low of $96.42 and a 12-month high of $164.76. The stock has a market cap of $4.09 billion, a price-to-earnings ratio of -21.10 and a beta of 2.55.
Several research firms recently issued reports on GWPH. ValuEngine raised GW Pharmaceuticals PLC- from a “buy” rating to a “strong-buy” rating in a research note on Monday, July 2nd. BidaskClub raised GW Pharmaceuticals PLC- from a “hold” rating to a “buy” rating in a research note on Wednesday, May 9th. Zacks Investment Research lowered GW Pharmaceuticals PLC- from a “buy” rating to a “hold” rating in a research note on Friday, May 11th. Cowen reissued a “buy” rating and set a $165.00 price objective on shares of GW Pharmaceuticals PLC- in a research note on Wednesday, May 9th. Finally, Cantor Fitzgerald dropped their price objective on GW Pharmaceuticals PLC- from $235.00 to $211.00 and set an “overweight” rating for the company in a research note on Wednesday, August 8th. Three research analysts have rated the stock with a hold rating and six have given a buy rating to the company. The stock presently has a consensus rating of “Buy” and an average price target of $179.14.
GW Pharmaceuticals PLC- Company Profile
GW Pharmaceuticals plc, a biopharmaceutical company, engages in discovering, developing, and commercializing cannabinoid prescription medicines using botanical extracts derived from the Cannabis plant. The company operates through three segments: Commercial, Sativex Research and Development, and Pipeline Research and Development.
Read More: Google Finance Portfolio Workaround
Want to see what other hedge funds are holding GWPH? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for GW Pharmaceuticals PLC- (NASDAQ:GWPH).
Receive News & Ratings for GW Pharmaceuticals PLC- Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GW Pharmaceuticals PLC- and related companies with MarketBeat.com's FREE daily email newsletter.